REFRACTORY NON-HODGKIN LYMPHOMA

This early-stage study is testing the safety of combining two targeted cancer drugs, loncastuximab tesirine and venetoclax, for people with non-Hodgkin lymphoma that has come back or hasn't responded to at least two prior treatments. The main goal is to find the safest and most e…

This study is testing whether the immunotherapy drug nivolumab can help control blood cancers that have returned, stopped responding, or are still detectable after a patient has already received CAR-T cell therapy. It is for adults with specific types of lymphoma, leukemia, or mu…

This early-stage study is testing the safety and best dose of a new drug, pevonedistat, when given with an existing drug, ibrutinib. It is for adults with chronic lymphocytic leukemia or non-Hodgkin lymphoma that has come back or stopped responding to other treatments. The goal i…

This study is testing a drug called tipifarnib in children and young adults whose advanced cancers have a specific genetic change in a gene called HRAS. The goal is to see if the drug can shrink tumors and control the disease. Participants take the drug as a pill or through a fee…

This study is testing a drug called larotrectinib in children and young adults (ages 1-21) whose advanced solid tumors, lymphomas, or histiocytic disorders have returned or not responded to standard treatments. The drug is given to patients whose tumors have a specific genetic ch…

This study is testing if adding a low dose of radiation therapy is safe and practical for patients before they receive a CAR-T cell treatment for B-cell lymphoma that has returned or not responded to other therapies. The goal is to see if this combination can improve outcomes for…

This study is testing a targeted drug called selpercatinib in children and young adults with advanced or returning cancers that have specific changes in a gene called RET. The goal is to see if the drug can shrink tumors and control the cancer's growth. Participants take the drug…

This early-stage study is testing the safety and best dose of a combination of two drugs, tazemetostat and belinostat, for people with lymphoma that has come back or hasn't responded to other treatments. The goal is to see if this combination can help control the cancer. The stud…

This study is testing a drug called ensartinib in children and young adults whose advanced cancers have specific genetic changes (ALK or ROS1). The goal is to see if the drug can shrink tumors or stop them from growing in patients whose cancer has come back or hasn't responded to…

This study is testing an oral drug called ulixertinib in children and adolescents whose advanced cancers have not responded to standard treatments and have a specific genetic change in a cell pathway called MAPK. The main goal is to see if the drug can shrink tumors and control t…

This study is testing a personalized approach for children and young adults with advanced cancers that have come back or stopped responding to standard treatments. Doctors first test the genetic makeup of a patient's tumor to look for specific changes. If a matching change is fou…

This early-phase trial is testing the safety and best dose of a two-drug combination (selinexor and choline salicylate) for adults with advanced blood cancers that have returned or stopped responding to standard treatments. The study includes patients with non-Hodgkin lymphoma, H…

This study is testing a drug called ivosidenib in children and young adults (ages 1-21) whose cancers have returned or not responded to standard treatments. The drug is given as a daily pill and is designed to specifically block cancer growth in tumors that have a particular gene…

This early-stage study is testing a new oral drug called BGB-21447 in adults with certain advanced blood cancers that have returned or stopped responding to other treatments. The main goals are to find a safe dose and see how the body processes the drug. Researchers will also loo…

This study is testing a drug called erdafitinib in children and young adults with advanced cancers that have returned or not responded to standard treatments. It is for patients whose tumors have specific genetic changes (FGFR mutations). The goal is to see if the drug, which is …